Solbec Pharmaceuticals has received the International...

Solbec Pharmaceuticals has received the International Preliminary Examination Report (IPER) for its manufacturing patent application for the method of separation of triglycoalkaloid’s. The examiners have found that all 57 claims in the application are novel, inventive and have industrial applicability.

This IPER follows the recent IPER on our patent application for the Cancer receptor “Rhamnose Binding Protein” in which all 27 claims were found to be inventive, novel and have industrial applicability.

These applications are now moving into the national phases with Solbec instructing its Patent attorneys to lodge the Rhamnose Binding Protein patent application in Canada, Japan, China, Europe, New Zealand and India.

Applications in Australia and the USA were filed some time ago and are currently pending.